Published in Cancer Weekly, August 5th, 1996
The information provided by ProstaScint should be considered in conjunction with other available diagnostic information. Thomas J. McKearn, Cytogen, stated, "Existing non-invasive diagnostic agents such as CT and MRI add little to the patient's or the physician's ability to predict whether the cancer has spread to areas outside the prostatic bed and into the patient's...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.